[et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”88f366a5-bf49-48d9-a338-ab22706b73e7″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||||false|false” custom_padding_tablet=”10px||||false|false” custom_padding_phone=”0px||||false|false” custom_padding_last_edited=”on|phone” global_colors_info=”{}”][dipi_breadcrumbs _builder_version=”4.27.4″ _module_preset=”default” max_width=”800px” global_module=”5132″ saved_tabs=”all” global_colors_info=”{}”][\/dipi_breadcrumbs][et_pb_divider color=”#EEEEEE” _builder_version=”4.16″ _module_preset=”default” max_width=”800px” min_height=”1px” height=”20px” custom_margin=”||3px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ _module_preset=”8738c908-7375-4c6c-99a7-9f91f8a3c099″ header_font_size=”56px” max_width=”800px” custom_margin=”||17px|||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”#ceo” button_text=”A word from the CEO” _builder_version=”4.17.3″ _module_preset=”8a97d634-613e-4957-a347-3fdc5d1378cf” custom_margin=”|-22px||||” custom_padding=”|28px||||” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https:\/\/idldiagnostics.com\/investors\/corporate-governance\/board-of-directors\/” button_text=”Board of directors” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https:\/\/idldiagnostics.com\/investors\/corporate-governance\/management\/” button_text=”Management” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics targets different patient groups in different parts of the world.<\/p>\n
and our biomarkers, we develop tests that are clinically useful and economically viable, making us a valuable and relevant diagnostic partner for healthcare professionals. We provide rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, and easy to perform – all of which are important criteria for the healthcare and payer community.<\/p>\n
can contribute to one of the \u2018three imperatives\u2019 for reducing the burden of disease: diagnostics, therapeutics and vaccines. In the wake of covid-19, it is fair to say that diagnostics has been given a well-deserved place in the healthcare limelight. With a growing number of elderly people around the world in combination with an increase in the incidence of chronic diseases, the need for accurate diagnostics is essential.<\/p>\n
by executing our strategy of increasing sales volumes in existing markets, obtaining market approvals in other prioritized markets, and continuously developing the next generation of IVD tests. With a pipeline that meets current and future demands, we stay relevant not only to patients, but to all our stakeholders. IDL Diagnostics was first listed in 2016 and our shares are traded on Stockholm Nasdaq First North.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
from R&D to manufacturing and marketing, we have the flexibility of a small company and the characteristics of a big company. It enables us to be a fast mover in the fast growing field of IVD-tests This is critical for us to be able deliver on our vision to be valuable and relevant diagnostic partner in oncology healthcare.<\/p>\n
[\/et_pb_text][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2021\/05\/about-us_2.jpg” title_text=”about us_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”ceo” _builder_version=”4.17.3″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ global_colors_info=”{}”][et_pb_row _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/05\/word-from-CEO.jpg” title_text=”word-from-CEO” _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.17.3″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
There are several advantages with the name change to IDL Diagnostics. Firstly, IDL Biotech is a well-known name among our partners and customers. Secondly, it becomes clear that we are active in diagnostics when we add \u201cDiagnostics\u201d to the company name . Thirdly, it creates a clear link to IDL Biotech and its product portfolio, which currently accounts for the majority of our turnover. This does not mean that we are reducing the work on our product AroCell TK 210 ELISA. The work continues with the main focus on introducing the TK1 marker on automated platforms, as I mentioned above. Overall, the new name will serve as a unifying name for all our products, while clarifying our business and will be a good support in our continued sales work<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
With the successful integration of IDL Biotech into the AroCell Group, we have accelerated our efforts to advance oncology diagnostics with the next generation of in vitro (IVD) tests. We are proud to say that today AroCell possesses all the capabilities of a \u201clarge\u201d company – including an R&D organization with scalable manufacturing facilities as well as a marketing and a sales organization – while at the same time maintaining the agility of a \u201csmall\u201d company.<\/p>\n
Along with therapeutics and vaccines, diagnostics constitutes the critical \u201cthird imperative\u201d for reducing the disease burden for many severe diseases. Diagnostics can provide critical information at every step of the patient journey \u2013 from diagnosis through to monitoring, screening and prognosis. Diagnostics improve patient care and contribute to protecting a patient\u2019s health and limiting healthcare spending. The pandemic has put a spotlight on IVDs in the global effort to combat and control the spread of SARS-CoV-2, the virus that causes COVID-19. Beyond the unprecedented general awareness of diagnostics that this has created, we believe that it will impact both healthcare professionals and patient expectations for diagnostic test availability, speed and accuracy.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Healthcare providers and payers look for tests that improve decision-making, are non-invasive, cost effective, and easy to perform. IDL Diagnostic\u2019s tests tick all these boxes. Our product portfolio comprises three test categories based on three biomarkers: rapid tests, platform tests, and laboratory tests. Rapid tests are the fastest growing category with the highest margins and is a strategic priority for IDL Diagnostics.<\/p>\n
Overall, the main market driver for the diagnostic market is the increased prevalence of chronic diseases. As just one example, the incidence of cancer is expected to grow by 47 percent globally over the next 20 years, leading to almost 30 million cancer cases by 2040. Therefore, there are significant expectations on advancements in oncology diagnostics based on new biomarkers and new technologies. We hope to contribute to meeting this growing demand with the next generation of combination tests.<\/p>\n
IDL Diagnostics is committed to becoming a gold standard in oncologic diagnostics and the preferred choice for healthcare providers. With our experienced and highly engaged team, board and stakeholder network, we will do everything we can to make that a reality.<\/p>\n
\nPlease join us on our journey!
Anders Hultman, CEO of IDL Diagnostics<\/p>\n<\/blockquote>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” global_module=”2293″ saved_tabs=”all” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_menu menu_id=”25″ disabled_on=”on|on|off” _builder_version=”4.18.0″ _module_preset=”_initial” background_color=”#F8F8F8″ global_colors_info=”{}”][\/et_pb_menu][et_pb_sidebar area=”et_pb_widget_area_1″ disabled_on=”off|off|on” _builder_version=”4.16″ _module_preset=”2efbbc8f-7ecb-4fe3-9956-d83a8a0e7a74″ background_color=”#F8F8F8″ global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ _module_preset=”default” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2175″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.27.4″ _module_preset=”default” width=”90%” max_width=”2000px” global_colors_info=”{}”][et_pb_column type=”1_2″ module_class=”ds-vertical-align” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#21242A” global_colors_info=”{}”]<\/p>\n
Investors<\/h6>\n
We are listed on NASDAQ First North Growth Market.<\/h3>\n
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/investors\/” button_text=”Read more about investing” _builder_version=”4.18.0″ _module_preset=”5e8c1032-9074-49bb-92a6-99c20ecc3d02″ global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/MG_3045.jpg” title_text=”_MG_3045″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ _module_preset=”default” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2428″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.27.4″ _module_preset=”default” width=”90%” max_width=”2000px” global_colors_info=”{}”][et_pb_column type=”1_2″ module_class=”ds-vertical-align” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Bacteriology<\/h6>\n
An effective typhoid test<\/h3>\n
Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella<\/em> enterica. IDL Biotechs product TUBEX\u00ae TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/products\/bacteriology\/” button_text=”Read more about bacteriology” _builder_version=”4.18.0″ _module_preset=”5e8c1032-9074-49bb-92a6-99c20ecc3d02″ global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/girl-water.jpeg” title_text=”Water is Life for African Children, Little Gorgeous Black Girl Drinking from Tap” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ _module_preset=”default” custom_padding_tablet=”||0px||false|false” custom_padding_phone=”” global_module=”2365″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.27.4″ _module_preset=”default” width=”90%” max_width=”2000px” global_colors_info=”{}”][et_pb_column type=”1_2″ module_class=”ds-vertical-align” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Oncology<\/h6>\n
Diagnostics for oncology<\/h3>\n
Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.<\/span><\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/idldiagnostics.com\/products\/oncology\/” button_text=”Read more about oncology” _builder_version=”4.22.1″ _module_preset=”5e8c1032-9074-49bb-92a6-99c20ecc3d02″ global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/girl-sunset.jpeg” title_text=”Happy smiling running beagle dog portrait with tongue out and owner female jogging by the mounting meadow grass path. Walking in nature with pets, happy healthy active people lifestyle concept image.” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t